Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
International Journal of Oncology|September 12, 2006
Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markersMartina Müller, Martina Meyer, Tobias Schilling, et al.
Investigational New Drugs|July 4, 2012
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancerChristian Manegold, Johan Vansteenkiste, Felipe Cardenal, et al.
Scientific Reports|July 15, 2017
Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistanceLukas Klameth, Barbara Rath, Maximilian Hochmaier, et al.
Anticancer Research|September 12, 2013
Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvementAndreas Pircher, Ines Kristin Wasle, Michael Mian, et al.
Annals of Hematology|August 21, 2009
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphomaMichael A Fridrik, Hubert Hausmaninger, Alois Lang, et al.
Annals of Hematology|February 24, 2005
Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR)David Nachbaur, Hildegard T Greinix, Elisabeth Koller, et al.
Lung Cancer (Amsterdam, Netherlands)|March 30, 2006
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialThomas Brodowicz, Maciej Krzakowski, Matjaz Zwitter, et al.
European Journal of Haematology|May 17, 2021
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemiaSigrid Machherndl-Spandl, Eva Jäger, Agnes Barna, et al.
The Lancet. Oncology|February 22, 2015
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 studyLuis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, et al.
International Journal of Molecular Sciences|April 30, 2020
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 PatientsKlaus Geissler, Eva Jäger, Agnes Barna, et al.
Pageof 3